Extrapulmonary Tuberculosis: Challenges in Diagnosis and Treatment - Case series
References
- WHO. Global tuberculosis report 2022. 2022. Available from: https://www.who.int/publications/i/item/9789240061729. Accessed June 20, 2022.
- Sharma SK, Mohan A, Kohli M. Extrapulmonary tuberculosis. Expert Review of Respiratory Medicine. 2021;15(7): 931–948. doi:10.1080/17476348.2021.1927718.
- Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberculosis and Respiratory Diseases (Seoul). 2015;78(2): 47–55. doi:10.4046/trd.2015.78.2.47.
- Prakash AK, Datta B, Goyal P, Chatterjee P, Gupta G. GENEXPERT gives early diagnosis in early tuberculosis. European Respiratory Journal. 2016;48: A2775. doi:10.1183/13993003. congress-2016.PA2775.
- Balbi GGM, Machado-Ribeiro F, Marques CDL, Signorelli F, Levy RA. The interplay between tuberculosis and systemic lupus erythematosus. Current Opinion in Rheumatology. 2018;30(4): 395–402. doi:10.1097/BOR.0000000000000493.
- Dunn RN, Ben Husien M. Spinal tuberculosis: review of current management. The Bone & Joint Journal. 2018;100-B(4): 425–431. doi:10.1302/0301-620X.100B4.BJJ-2017-1040.R1.
- Yang SC, Lai YY, Huang MC, Tsai CS, Wang JL. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus. 2018;27(11): 1819–1827. doi:10.1177/0961203318792352.
- WHO. WHO Guidelines for treatment of tuberculosis. WHO; 2022. Available from: https://www.who.int/publications/i/item/9789240048126. Accessed June 20, 2022.
- Dobler CC. 2016. Biologic agents and tuberculosis. Microbiol Spectrum 4(6):TNMI7-0026-2016. doi:10.1128/microbiolspec. TNMI7-0026-2016.
- Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheuma. 2009;60(7): 1884–1894. doi:10.1002/art.24632.
- Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61(9): 791–794. doi:10.1136/thx.2006.058867.
- Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infection Control & Hospital Epidemiology. 2005;26(3): 273–280. doi:10.1086/502539.
- Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulmonary Medicine. 2013;2013: ArticleID828939,11 pages. doi:10.1155/2013/828939.
- Abbara A, Chitty S, Roe JK, Ghani R, Collin SM, Ritchie A, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infectious Diseases. 2017;17: 231. doi:10.1186/s12879-017-2330-z.
- Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection— associated tuberculosis: the epidemiology and the response. Clinical Infectious Diseases. 2010;50(Suppl_3): S201–S207. doi:10.1086/651492.
Language: English
Page range: 163 - 170
Published on: Nov 7, 2024
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: Volume open
Related subjects:
© 2024 Ștefania Florina Oprea, Cătălina Elena Ene, Ionela Belaconi, Stefan Dumitrache-Rujinski, Claudia-Lucia Toma, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.